Mylan PE Ratio 2006-2018 | MYL

Current and historical p/e ratio for Mylan (MYL) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Mylan PE ratio as of November 16, 2018 is 7.41.
Mylan PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-16 34.92 49.89
2018-09-30 36.60 $0.70 52.29
2018-06-30 36.14 $0.86 42.02
2018-03-31 41.17 $1.34 30.72
2017-12-31 42.31 $1.29 32.80
2017-09-30 31.37 $1.61 19.48
2017-06-30 38.82 $1.22 31.82
2017-03-31 38.99 $1.00 38.99
2016-12-31 38.15 $0.91 41.92
2016-09-30 38.12 $0.51 74.75
2016-06-30 43.24 $1.57 27.54
2016-03-31 46.35 $1.56 29.71
2015-12-31 54.07 $1.66 32.57
2015-09-30 40.27 $1.75 23.01
2015-06-30 67.86 $2.18 31.13
2015-03-31 59.35 $2.18 27.22
2014-12-31 56.37 $2.34 24.09
2014-09-30 45.49 $2.32 19.61
2014-06-30 51.56 $1.46 35.32
2014-03-31 48.83 $1.60 30.52
2013-12-31 43.40 $1.58 27.47
2013-09-30 38.17 $1.52 25.11
2013-06-30 31.03 $1.63 19.04
2013-03-31 28.96 $1.50 19.30
2012-12-31 27.45 $1.53 17.94
2012-09-30 24.37 $1.44 16.92
2012-06-30 21.37 $1.29 16.57
2012-03-31 23.45 $1.29 18.18
2011-12-31 21.46 $1.22 17.59
2011-09-30 16.99 $0.93 18.27
2011-06-30 24.67 $0.90 27.41
2011-03-31 22.66 $0.73 31.04
2010-12-31 21.13 $0.70 30.19
2010-09-30 18.81 $0.70 26.87
2010-06-30 17.04 $0.24 71.00
2010-03-31 22.71 $0.27 84.11
2009-12-31 18.43 $0.23 80.13
2009-09-30 16.01 $0.09 177.89
2009-06-30 13.05 $0.67 19.48
2009-03-31 13.41 $0.45 29.80
2008-12-31 9.89 $-1.17 0.00
2008-09-30 11.42 $-6.08 0.00
2008-06-30 12.07 $-5.93 0.00
2008-03-31 11.60 $-5.58 0.00
2007-12-31 14.06 $-4.43 0.00
2007-09-30 15.96 $1.24 12.87
2007-06-30 18.19 $1.00 18.19
2007-03-31 21.07 $1.03 20.46
2006-12-31 19.84 $1.34 14.81
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $18.006B $11.908B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $53.085B 9.11
Teva Pharmaceutical Industries (TEVA) Israel $22.626B 6.93
Bausch Health Cos (BHC) Canada $8.859B 6.41
Dr Reddy's Laboratories (RDY) India $5.791B 23.13
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.571B 4.29
Supernus Pharmaceuticals (SUPN) United States $2.296B 21.75
Amphastar Pharmaceuticals (AMPH) United States $0.953B 103.35
Akorn (AKRX) United States $0.860B 0.00
Homology Medicines (FIXX) United States $0.769B 0.00
Assembly Biosciences (ASMB) United States $0.628B 0.00
CymaBay Therapeutics (CBAY) United States $0.574B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.455B 0.00
Voyager Therapeutics (VYGR) United States $0.405B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.296B 0.00
Teligent (TLGT) United States $0.137B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.093B 0.00
Aevi Genomic Medicine (GNMX) United States $0.071B 0.00
Acasti Pharma (ACST) Canada $0.057B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.029B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00